BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow ® disease ...
Findings from pediatric trials showed left ventricular opacification with Definity was successful and provided important information to guide patient management. The Food and Drug Administration (FDA) ...
Lantheus Holdings, Inc. LNTH recently announced that the FDA has approved the supplemental new drug application for DEFINITY (Perflutren Lipid Microsphere) as an ultrasound-enhancing agent for use in ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved perflutren lipid microsphere injection to improve ultrasound imaging in pediatric patients. The ...
NORTH BILLERICA, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results